173 related articles for article (PubMed ID: 22170099)
1. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Michaelis M; Rothweiler F; Barth S; Cinatl J; van Rikxoort M; Löschmann N; Voges Y; Breitling R; von Deimling A; Rödel F; Weber K; Fehse B; Mack E; Stiewe T; Doerr HW; Speidel D; Cinatl J
Cell Death Dis; 2011 Dec; 2(12):e243. PubMed ID: 22170099
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.
Laroche A; Tran-Cong K; Chaire V; Lagarde P; Hostein I; Coindre JM; Chibon F; Neuville A; Lesluyes T; Lucchesi C; Italiano A
PLoS One; 2015; 10(10):e0137794. PubMed ID: 26427052
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
[TBL] [Abstract][Full Text] [Related]
4. Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3.
Boyarskikh U; Pintus S; Mandrik N; Stelmashenko D; Kiselev I; Evshin I; Sharipov R; Stegmaier P; Kolpakov F; Filipenko M; Kel A
BMC Med Genomics; 2018 Feb; 11(Suppl 1):12. PubMed ID: 29504919
[TBL] [Abstract][Full Text] [Related]
5. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.
Wei SJ; Chee S; Yurlova L; Lane D; Verma C; Brown C; Ghadessy F
Oncotarget; 2016 May; 7(22):32232-46. PubMed ID: 27057630
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells.
Rodrigo MAM; Buchtelova H; Jimenez AMJ; Adam P; Babula P; Heger Z; Adam V
Cells; 2019 Mar; 8(3):. PubMed ID: 30871063
[TBL] [Abstract][Full Text] [Related]
7. Identification of miRNAs contributing to neuroblastoma chemoresistance.
Ayers D; Mestdagh P; Van Maerken T; Vandesompele J
Comput Struct Biotechnol J; 2015; 13():307-19. PubMed ID: 25973145
[TBL] [Abstract][Full Text] [Related]
8. Towards image-based cancer cell lines authentication using deep neural networks.
Mzurikwao D; Khan MU; Samuel OW; Cinatl J; Wass M; Michaelis M; Marcelli G; Ang CS
Sci Rep; 2020 Nov; 10(1):19857. PubMed ID: 33199764
[TBL] [Abstract][Full Text] [Related]
9. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
[TBL] [Abstract][Full Text] [Related]
10. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
11. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action.
Wang W; Wang X; Rajaei M; Youn JY; Zafar A; Deokar H; Buolamwini JK; Yang J; Foster JH; Zhou J; Zhang R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291373
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.
Hoffman-Luca CG; Ziazadeh D; McEachern D; Zhao Y; Sun W; Debussche L; Wang S
Clin Cancer Res; 2015 Jun; 21(11):2558-68. PubMed ID: 25754349
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect.
Afonso J; Barbosa-Matos C; Silvestre R; Pereira-Vieira J; Gonçalves SM; Mendes-Alves C; Parpot P; Pinto J; Carapito Â; Guedes de Pinho P; Santos L; Longatto-Filho A; Baltazar F
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611096
[TBL] [Abstract][Full Text] [Related]
14. New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics.
Grigoreva T; Sagaidak A; Novikova D; Tribulovich V
Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540160
[TBL] [Abstract][Full Text] [Related]
15. Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma.
Vella V; Ditsiou A; Chalari A; Eravci M; Wooller SK; Gagliano T; Bani C; Kerschbamer E; Karakostas C; Xu B; Zhang Y; Pearl FMG; Lopez G; Peng L; Stebbing J; Klinakis A; Giamas G
Adv Sci (Weinh); 2024 Apr; 11(15):e2306027. PubMed ID: 38353396
[TBL] [Abstract][Full Text] [Related]
16. Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.
Silva A; Félix A; Cerqueira M; Gonçalves CS; Sampaio-Marques B; Longatto-Filho A; Baltazar F; Afonso J
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140029
[TBL] [Abstract][Full Text] [Related]
17. Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma.
Jacob M; Wiedemann S; Brücher D; Pieper NM; Birkhold M; Särchen V; Jeroch J; Demes MC; Gretser S; Braun Y; Gradhand E; Rothweiler F; Michaelis M; Cinatl J; Vogler M
Br J Cancer; 2023 Nov; 129(10):1667-1678. PubMed ID: 37723317
[TBL] [Abstract][Full Text] [Related]
18. Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.
Blagosklonny MV
Oncotarget; 2023 Mar; 14():193-206. PubMed ID: 36913303
[TBL] [Abstract][Full Text] [Related]
19. Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy.
Afonso J; Gonçalves C; Costa M; Ferreira D; Santos L; Longatto-Filho A; Baltazar F
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765947
[TBL] [Abstract][Full Text] [Related]
20. Increased HRD score in cisplatin resistant penile cancer cells.
Winkelmann R; Bankov K; Döring C; Cinatl J; Grothe S; Rothweiler F; Michaelis M; Schmitt C; Wild PJ; Demes M; Cinatl J; Vallo S
BMC Cancer; 2022 Dec; 22(1):1352. PubMed ID: 36564761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
